DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

MTD·Mettler-Toledo International Inc.

$.
+. (+.%)
After Hours
High
$1,303.45
Open
$1,295.92
Market Cap
26.19B
52W High
$1,525.17
Low
$1,279.36
P. Close
$1,296.21
P/E
29.93
52W Low
$1,023.05
Fwd P/E
25.28
DailyIQ Est.
$1333.13
Technical Score (1D)
64
BUY
News Sentiment
50
MIXED
Mettler‑Toledo was recently dropped from the Russell 1000 Dynamic Index, a move that signals softer organic revenue growth and suggests the company may not meet the index’s performance thresholds. Management’s emphasis on defending margins amid rising tariff‑related costs and input price pressure indicates that near‑term earnings resilience could be under strain. The index removal could trigger portfolio rebalancing by index‑tracking funds, potentially adding selling pressure in the next few trading days. Analysts have responded by adjusting price targets—Evercore ISI lifted its target to $1,350 and Argus Research raised it to $1,425—reflecting confidence in margin expansion but also a cautious view of cost dynamics. These upgrades come after the company’s Q1 2026 results, which showed a 7.2% revenue increase but highlighted weak organic growth and a valuation premium that some view as unsustainable. The combination of a higher target and a recent downgrade by Barclays to $1,300 indicates a split view on near‑term upside, underscoring uncertainty that could influence short‑term volatility. Options activity has spiked, with increased open interest and implied volatility, suggesting traders are positioning for a potential move around the upcoming Q2 earnings release. The next earnings announcement, scheduled for July 30, will be a key watch point; guidance on revenue, operating margin, and cost‑control initiatives will clarify whether the company can sustain profitability amid commodity price swings. In the interim, investors should monitor any updates on tariff‑related cost management, raw material price trends, and the performance of the measurement‑equipment sector, as these factors will shape MTD’s near‑term trajectory.
Earnings Summary
Mettler‑Toledo International Inc. (MTD) supplies precision instruments and related services to laboratory and industrial customers worldwide, operating primarily in the diagnostics and research sector of healthcare. The company’s dual‑segment model—laboratory instruments and industrial instruments—serves life science, food production, and chemical industries, positioning it within a niche yet essential market for analytical and weighing solutions. In the most recent two quarters, MTD’s revenue fell from $1,129.74 million in Q4 2025 to $947.13 million in Q1 2026, a 16.8% decline, while EPS dropped from $13.36 to $8.91, a 33.5% decrease; this contrasts with the prior two quarters where revenue rose from $983.22 million in Q2 2025 to $1,029.70 million in Q3 2025 and EPS climbed from $10.09 to $11.15. Despite the recent downturn, MTD consistently beat earnings estimates in all six quarters reported, with Q4 2025 revenue surpassing the $1,115.61 million estimate and Q1 2026 revenue narrowly missing the $951.22 million forecast. Historically, the company has maintained positive YoY growth, with revenue up 8.2% in Q4 2025 versus Q4 2024 and 7.2% in Q1 2026 versus Q1 2025, and EPS rising 7.7% and 8.8% respectively, underscoring a resilient earnings trajectory even amid market volatility. Recent news highlights an upcoming Q2 2026 earnings release that will shed light on revenue, margins, and potential new product launches; analysts have raised price targets to $1,350–$1,425 amid confidence in cost‑control initiatives, yet concerns remain over a 2.7% YoY organic revenue growth lagging peers, prompting scrutiny of demand recovery in life sciences and commodity‑price exposure. Investors should watch the forthcoming earnings call for guidance on full‑year revenue growth, margin expansion, and any updates on supply‑chain constraints or regulatory changes, as these factors will shape the company’s valuation trajectory in the next 10–15 trading days.

EPS

EstBeatMiss
$7.06$8.84$10.62$12.40$14.18Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$10.80 - -
Q1'26$8.79$8.91+1.4%
Q4'25$12.93$13.36+3.3%
Q3'25$10.66$11.15+4.6%
Q2'25$9.60$10.09+5.1%
Q1'25$7.88$8.19+3.9%

Revenue

EstBeatMiss
$847M$927M$1.0B$1.1B$1.2BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.0B - -
Q1'26$951M$947M-0.4%
Q4'25$1.1B$1.1B+1.3%
Q3'25 - $1.0B -
Q2'25 - $983M -
Q1'25 - $884M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MTD Stock Snapshot

MTD is currently trading at $1296.17, giving Mettler-Toledo International Inc. a market cap of 26.19B and a P/E ratio of 29.9. Today's range spans $1279.36–$1303.45, with shares opening at $1295.92 and moving down $0.04 (0.0%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 50/100.

Over the past year MTD has traded between $1023.05 and $1525.17 - the current price is +26.7% off the 52-week low and -15.0% from the high. 22 analysts cover the stock with a Hold consensus and a mean 12-month target of $1315.33 (range $1194.00–$1550.00), implying upside of +1.5%.

It's a pause for MTD: technical score 64/100 (HOLD), sentiment neutral (50/100), price $1296.17 (in the middle of its 52-week range). (P/E: 29.9) At 26.19B in Healthcare market cap, pauses like this often occur when the stock has run ahead of near-term fundamental catalysts and is waiting for earnings or macro data to validate the prior move. Annual range: $1023.05–$1525.17. The consolidation is the story for now.

In neutral phases, large-cap Healthcare names like MTD are often where sector rotation debates play out quietly — at 26.19B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 64/100 (HOLD) and neutral sentiment (50/100) at $1296.17 (in the middle of its 52-week range) describe a stock that is being considered rather than avoided.